Hypertension control: economics and lifestyle issues: proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995
Gespeichert in:
| Format: | Tagungsbericht Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Basingstoke
Stockton
1996
|
| Schriftenreihe: | Journal of human hypertension
10,Suppl.2 |
| Schlagworte: | |
| Beschreibung: | Einzelaufnahme eines Zeitschr.-Suppl. |
| Beschreibung: | 38 S. graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV011542388 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 970922s1996 d||| |||| 10||| eng d | ||
| 035 | |a (OCoLC)231707015 | ||
| 035 | |a (DE-599)BVBBV011542388 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 245 | 1 | 0 | |a Hypertension control: economics and lifestyle issues |b proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 |c proceedings ed.: Arun Chockalingam |
| 264 | 1 | |a Basingstoke |b Stockton |c 1996 | |
| 300 | |a 38 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Journal of human hypertension |v 10,Suppl.2 | |
| 500 | |a Einzelaufnahme eines Zeitschr.-Suppl. | ||
| 650 | 0 | 7 | |a Kosten-Nutzen-Analyse |0 (DE-588)4032589-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antihypertonikum |0 (DE-588)4002286-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Hypertonie |0 (DE-588)4026372-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Risikofaktor |0 (DE-588)4050131-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gesundheitsökonomie |0 (DE-588)4130935-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1995 |z Ottawa |2 gnd-content | |
| 689 | 0 | 0 | |a Hypertonie |0 (DE-588)4026372-1 |D s |
| 689 | 0 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | 2 | |a Gesundheitsökonomie |0 (DE-588)4130935-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Antihypertonikum |0 (DE-588)4002286-9 |D s |
| 689 | 1 | 1 | |a Kosten-Nutzen-Analyse |0 (DE-588)4032589-1 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Hypertonie |0 (DE-588)4026372-1 |D s |
| 689 | 2 | 1 | |a Risikofaktor |0 (DE-588)4050131-0 |D s |
| 689 | 2 | |5 DE-604 | |
| 700 | 1 | |a Chockalingam, Arun |e Sonstige |4 oth | |
| 711 | 2 | |a World Conference on Hypertension Control |d 1995 |c Ottawa |j Sonstige |0 (DE-588)1234450-3 |4 oth | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-007770070 | ||
Datensatz im Suchindex
| _version_ | 1804126065519493120 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV011542388 |
| ctrlnum | (OCoLC)231707015 (DE-599)BVBBV011542388 |
| format | Conference Proceeding Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01957nam a2200481 cb4500</leader><controlfield tag="001">BV011542388</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">970922s1996 d||| |||| 10||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)231707015</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV011542388</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypertension control: economics and lifestyle issues</subfield><subfield code="b">proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995</subfield><subfield code="c">proceedings ed.: Arun Chockalingam</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basingstoke</subfield><subfield code="b">Stockton</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">38 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Journal of human hypertension</subfield><subfield code="v">10,Suppl.2</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Einzelaufnahme eines Zeitschr.-Suppl.</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kosten-Nutzen-Analyse</subfield><subfield code="0">(DE-588)4032589-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antihypertonikum</subfield><subfield code="0">(DE-588)4002286-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hypertonie</subfield><subfield code="0">(DE-588)4026372-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Risikofaktor</subfield><subfield code="0">(DE-588)4050131-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesundheitsökonomie</subfield><subfield code="0">(DE-588)4130935-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1995</subfield><subfield code="z">Ottawa</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Hypertonie</subfield><subfield code="0">(DE-588)4026372-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Gesundheitsökonomie</subfield><subfield code="0">(DE-588)4130935-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Antihypertonikum</subfield><subfield code="0">(DE-588)4002286-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Kosten-Nutzen-Analyse</subfield><subfield code="0">(DE-588)4032589-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Hypertonie</subfield><subfield code="0">(DE-588)4026372-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Risikofaktor</subfield><subfield code="0">(DE-588)4050131-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chockalingam, Arun</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="711" ind1="2" ind2=" "><subfield code="a">World Conference on Hypertension Control</subfield><subfield code="d">1995</subfield><subfield code="c">Ottawa</subfield><subfield code="j">Sonstige</subfield><subfield code="0">(DE-588)1234450-3</subfield><subfield code="4">oth</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007770070</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1995 Ottawa gnd-content |
| genre_facet | Konferenzschrift 1995 Ottawa |
| id | DE-604.BV011542388 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:11:32Z |
| institution | BVB |
| institution_GND | (DE-588)1234450-3 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007770070 |
| oclc_num | 231707015 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | 38 S. graph. Darst. |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Stockton |
| record_format | marc |
| series2 | Journal of human hypertension |
| spelling | Hypertension control: economics and lifestyle issues proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 proceedings ed.: Arun Chockalingam Basingstoke Stockton 1996 38 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Journal of human hypertension 10,Suppl.2 Einzelaufnahme eines Zeitschr.-Suppl. Kosten-Nutzen-Analyse (DE-588)4032589-1 gnd rswk-swf Antihypertonikum (DE-588)4002286-9 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Hypertonie (DE-588)4026372-1 gnd rswk-swf Risikofaktor (DE-588)4050131-0 gnd rswk-swf Gesundheitsökonomie (DE-588)4130935-2 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1995 Ottawa gnd-content Hypertonie (DE-588)4026372-1 s Pharmakotherapie (DE-588)4076066-2 s Gesundheitsökonomie (DE-588)4130935-2 s DE-604 Antihypertonikum (DE-588)4002286-9 s Kosten-Nutzen-Analyse (DE-588)4032589-1 s Risikofaktor (DE-588)4050131-0 s Chockalingam, Arun Sonstige oth World Conference on Hypertension Control 1995 Ottawa Sonstige (DE-588)1234450-3 oth |
| spellingShingle | Hypertension control: economics and lifestyle issues proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 Kosten-Nutzen-Analyse (DE-588)4032589-1 gnd Antihypertonikum (DE-588)4002286-9 gnd Pharmakotherapie (DE-588)4076066-2 gnd Hypertonie (DE-588)4026372-1 gnd Risikofaktor (DE-588)4050131-0 gnd Gesundheitsökonomie (DE-588)4130935-2 gnd |
| subject_GND | (DE-588)4032589-1 (DE-588)4002286-9 (DE-588)4076066-2 (DE-588)4026372-1 (DE-588)4050131-0 (DE-588)4130935-2 (DE-588)1071861417 |
| title | Hypertension control: economics and lifestyle issues proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 |
| title_auth | Hypertension control: economics and lifestyle issues proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 |
| title_exact_search | Hypertension control: economics and lifestyle issues proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 |
| title_full | Hypertension control: economics and lifestyle issues proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 proceedings ed.: Arun Chockalingam |
| title_fullStr | Hypertension control: economics and lifestyle issues proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 proceedings ed.: Arun Chockalingam |
| title_full_unstemmed | Hypertension control: economics and lifestyle issues proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 proceedings ed.: Arun Chockalingam |
| title_short | Hypertension control: economics and lifestyle issues |
| title_sort | hypertension control economics and lifestyle issues proceedings of the official symposia of the world conference on hypertension control ottawa canada 21 june 1995 |
| title_sub | proceedings of the official symposia of the World Conference on Hypertension Control, Ottawa, Canada, 21 June, 1995 |
| topic | Kosten-Nutzen-Analyse (DE-588)4032589-1 gnd Antihypertonikum (DE-588)4002286-9 gnd Pharmakotherapie (DE-588)4076066-2 gnd Hypertonie (DE-588)4026372-1 gnd Risikofaktor (DE-588)4050131-0 gnd Gesundheitsökonomie (DE-588)4130935-2 gnd |
| topic_facet | Kosten-Nutzen-Analyse Antihypertonikum Pharmakotherapie Hypertonie Risikofaktor Gesundheitsökonomie Konferenzschrift 1995 Ottawa |
| work_keys_str_mv | AT chockalingamarun hypertensioncontroleconomicsandlifestyleissuesproceedingsoftheofficialsymposiaoftheworldconferenceonhypertensioncontrolottawacanada21june1995 AT worldconferenceonhypertensioncontrolottawa hypertensioncontroleconomicsandlifestyleissuesproceedingsoftheofficialsymposiaoftheworldconferenceonhypertensioncontrolottawacanada21june1995 |